LT2506840T - Hipoksija sukeliančio faktoriaus inhibitorių naudojimas - Google Patents

Hipoksija sukeliančio faktoriaus inhibitorių naudojimas

Info

Publication number
LT2506840T
LT2506840T LTEP10834883.0T LT10834883T LT2506840T LT 2506840 T LT2506840 T LT 2506840T LT 10834883 T LT10834883 T LT 10834883T LT 2506840 T LT2506840 T LT 2506840T
Authority
LT
Lithuania
Prior art keywords
hypoxxicity
factor inhibitors
inhibitors
factor
hypoxxicity factor
Prior art date
Application number
LTEP10834883.0T
Other languages
English (en)
Inventor
Yang Liu
Yin Wang
Yan Liu
Sami N. Malek
Pan ZENG
Original Assignee
OncoC4, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoC4, Inc. filed Critical OncoC4, Inc.
Publication of LT2506840T publication Critical patent/LT2506840T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP10834883.0T 2009-12-04 2010-06-25 Hipoksija sukeliančio faktoriaus inhibitorių naudojimas LT2506840T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26685609P 2009-12-04 2009-12-04
PCT/US2010/039910 WO2011068563A1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors

Publications (1)

Publication Number Publication Date
LT2506840T true LT2506840T (lt) 2021-06-25

Family

ID=44115219

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10834883.0T LT2506840T (lt) 2009-12-04 2010-06-25 Hipoksija sukeliančio faktoriaus inhibitorių naudojimas

Country Status (15)

Country Link
US (7) US9427413B2 (lt)
EP (2) EP2506840B1 (lt)
CN (2) CN102791260A (lt)
CA (1) CA2782527C (lt)
CY (1) CY1125365T1 (lt)
DK (1) DK2506840T3 (lt)
ES (1) ES2864743T3 (lt)
HR (1) HRP20210537T1 (lt)
HU (1) HUE053793T2 (lt)
LT (1) LT2506840T (lt)
PL (1) PL2506840T3 (lt)
PT (1) PT2506840T (lt)
SI (1) SI2506840T1 (lt)
SM (1) SMT202100234T1 (lt)
WO (1) WO2011068563A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791260A (zh) 2009-12-04 2012-11-21 生维医药科技有限公司 低氧诱导因子抑制剂的用途
CN103007293B (zh) * 2012-12-30 2014-04-02 中国人民解放军第三军医大学第一附属医院 具有靶向性的多肽-基因复合物及其制备方法和应用
US10898522B2 (en) 2015-08-19 2021-01-26 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
CN108495619A (zh) 2015-11-10 2018-09-04 儿研所儿童医学中心 棘霉素制剂及其制备方法和使用方法
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
CU20190092A7 (es) 2017-05-19 2020-10-20 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
CN110669871A (zh) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
US6416956B1 (en) 1999-08-13 2002-07-09 George Washington University Transcription factor, BP1
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
EP2322547A1 (en) * 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
CN1233844C (zh) * 2003-09-05 2005-12-28 上海第二医科大学附属瑞金医院 HIF－1α在治疗白血病药物的筛选中的应用
EP2316832B1 (en) * 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
EP1874824A4 (en) * 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) * 2006-05-02 2007-11-15 Emory University Hif-1 inhibitors and methods of use thereof
WO2008016702A2 (en) 2006-08-02 2008-02-07 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
CN102791260A (zh) 2009-12-04 2012-11-21 生维医药科技有限公司 低氧诱导因子抑制剂的用途

Also Published As

Publication number Publication date
US20170239315A1 (en) 2017-08-24
US20200147167A1 (en) 2020-05-14
CA2782527C (en) 2019-09-17
HRP20210537T1 (hr) 2021-05-14
EP3892264A3 (en) 2021-12-08
US20180177841A1 (en) 2018-06-28
US9623070B2 (en) 2017-04-18
EP2506840A4 (en) 2013-07-03
CA2782527A1 (en) 2011-06-09
CN102791260A (zh) 2012-11-21
DK2506840T3 (da) 2021-04-12
HUE053793T2 (hu) 2021-07-28
PL2506840T3 (pl) 2021-10-11
US20170035832A1 (en) 2017-02-09
US20120264697A1 (en) 2012-10-18
SMT202100234T1 (it) 2021-05-07
ES2864743T3 (es) 2021-10-14
EP3892264A2 (en) 2021-10-13
PT2506840T (pt) 2021-04-27
EP2506840B1 (en) 2021-01-06
US9427413B2 (en) 2016-08-30
US20210161991A1 (en) 2021-06-03
CY1125365T1 (el) 2024-02-16
SI2506840T1 (sl) 2021-08-31
WO2011068563A1 (en) 2011-06-09
CN109224064A (zh) 2019-01-18
EP2506840A1 (en) 2012-10-10
US20190255140A1 (en) 2019-08-22
US9877998B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
CY2019026I2 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
SMT201500271B (it) Inibitori di neprilisina
SMT201600291B (it) Inibitori di proteasi hcv
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
SMT201500043B (it) Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi
EP2299999A4 (en) STAT3 INHIBITORS
IL237582A0 (en) Cdk inhibitors
IL225867B (en) Coelenterazine substrates
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
EP2568812A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
FI20095529A0 (fi) Probioottien uusi käyttö
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
BR112012005382A2 (pt) inibidores de jak
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
EP2413941A4 (en) Renin Inhibitors
SMT201600031B (it) Composti eterociclici di fenossimetile